Table 4.

Ongoing phase 2 or 3 studies of PARPi in pancreatic cancer. Status as of July 21, 2021. Trials may be open to other tumor types, visit clinicaltrials.gov for the latest information.

PARPi	ClinicalTrials.gov Identifier (Name)	Trial Phase	Setting	Drugs	Status
Olaparib	NCT04666740 (POLAR)	Non-randomized phase 2	Maintenance after first or second-line therapy for metastatic disease. Germline mutations in homologous recombination (BRCA 1, BRCA2, PALB2, ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51, RAD51C, RTEL1) Platinum sensitive or resistant.	Pembrolizumab + Olaparib	Recruiting
	NCT04548752	Randomized phase 2	Maintenance therapy in metastatic disease with germline BRCA1 or BRCA2 mutations after first line platinum-based chemotherapy	Pembrolizumab + Olaparib Olaparib monotherapy	Recruiting
	NCT02677038	Non-Randomized phase 2	Metastatic and with mutations in homologous recombination (e.g. somatic BRCA mutation, FANC1, ATM or RAD51 mutations) or in patients with close family members with BRCA-driven cancers Negative for germline BRCA1 and BRCA2 mutations After at least one prior line of chemotherapy for metastatic disease and not have platinum-refractory cancer	Olaparib monotherapy	Active, not recruiting
	NCT04858334 (APOLLO)	Randomized phase 2	Adjuvant therapy following completion of surgery and chemotherapy Germline or somatic BRCA1, BRCA2 or PALB2 mutation	Olaparib monotherapy Placebo	Recruiting
	NCT02498613	Non-randomized phase 2	Maintenance therapy in advanced and metastatic pancreatic cancer	Cediranib + Olaparib	Recruiting
	NCT03682289	Non-randomized phase 2	Maintenance therapy in locally advanced or metastatic pancreatic cancer following at least one previous line of therapy	AZD6738 + Olaparib AZD6738	Recruiting
Rucaparib	NCT04171700 (LODESTAR)	Non-randomized phase 2	Maintenance therapy in unresectable, locally advanced, or metastatic solid tumors with deleterious mutations in BRCA1, BRCA2, PALB2, RAD51C or RAD51D. An expansion cohort is planned for patients with deleterious mutations in BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B. Following at least one but not more than three prior lines of systemic therapy	Rucaparib monotherapy	Recruiting
Niraparib	NCT03601923	Non-randomized phase 2	Maintenance therapy in metastatic or locally advanced pancreatic cancer with germline or somatic mutations in BRCA1, BRCA2, PALB2, CHEK2 or ATM. No progression on prior oxaliplatin-containing regimens	Niraparib monotherapy	Recruiting
	NCT04409002	Non-randomized phase 2	Metastatic pancreatic cancer	Niraparib + Dostarlimab + Radiation	Recruiting
	NCT03553004 (NIRA-PANC)	Non-randomized phase 2	Metastatic pancreatic cancer with germline or somatic mutations in genes involved in DNA repair following progression after 1–2 lines of chemotherapy	Niraparib Monotherapy	Recruiting
	NCT04493060	Non-randomized phase 2	Metastatic pancreatic cancer with germline or somatic BRCA1, BRCA2, or PALB2 mutations. Following progression on 1–2 prior lines of chemotherapy for metastatic disease, with prior exposure to a platinum agent.	Niraparib + Dostarlimab	Recruiting
	NCT03404960 (PARPVAX)	Randomized Phase 1b/2	Maintenance therapy for locally advanced or metastatic pancreatic cancer with stable disease after at least 16 weeks of platinum-based treatment	Niraparib + Nivolumab Niraparib + Ipilimumab	Recruiting
Talazoparib	No identified phase 2 or 3 trials
Veliparib	NCT02890355	Randomized phase 2	Metastatic pancreatic cancer with recurrence following one prior systemic regimen BRCA1, BRCA2, or other defects in homologous recombination repair	Veliparib + mFOlFIRI FOLFIRI	Active, Not Recruiting
	NCT01585805	Randomized phase 2	Locally advanced or metastatic pancreatic cancer with BRCA1, BRCA2, or PALB2 mutation. No prior treatment allowed for Arms A and B (GCV vs GC), up to two prior treatments allowed for Arm C (single agent veliparib)	Gemcitabine + Cisplatin and veliparib Gemcitabine + cisplatin Veliparib monotherapy	Active, not recruiting
Fluzoparib	NCT04300114	Randomized Double-Blind Phase 3	Maintenance therapy in patients with BRCA1/2 or PALB2-mutated pancreatic cancer that has not progressed on first-line platinum-based chemotherapy	Fluzoparib Placebo	Recruiting

GCV = Gemcitabine, cisplatin, veliparib. GC = Gemcitabine, Cisplatin, mFOLFIRI = modified fluorouracil, leucovorin, irinotecan.